Abstract 59P
Background
Although anti-epidermal growth factor receptor (EGFR) therapy has established efficacy in RAS/BRAF wild type (WT) mCRC, 10-20% of WT patients exhibit primary resistance to this treatment. Biomarker discovery has mainly focused on tumor-specific DNA mutations, which suffer from variable mutation frequencies among patients. Epigenetic abnormalities, such as promoter hypermethylation, represent a common and early event in carcinogenesis, making it promising for resistance detection. In fact, several studies have shown an association between DNA methylation patterns and resistance to anti-EGFR therapy in CRC. To validate and build upon these findings, we investigated the methylomes of primary tumors with resistant and responsive phenotypes.
Methods
We isolated DNA from 15 primary CRC tumors. These DNA samples were subjected to Enzymatic Methyl-Sequencing (EMSeq), creating a genome-wide methylation dataset. We calculated methylation levels at CpGs and evaluated their correlation with resistance status. Based on the methylation values, a differential methylation analysis was performed using a modified linear mixed regression model. The CpGs were ranked based on the largest Δmethylation values and most significant p-values across the three patient groups. We performed a false discovery rate (FDR) evaluation, which led to the selection of differentially methylated CpGs (DMCs) with the highest likelihood of being genuine associations. Additionally, the DMCs were used as input for gene set enrichment analysis (GSEA).
Results
The GSEA revealed significant enrichment in 1 KEGG and 8 Reactome pathways, including MAPK-related, Akt and Wnt signaling. A gene ontology (GO) overrepresentation analysis was conducted on the significant genes. Notably, the most prominent GO categories were GTPase activity for molecular function and response to oxidative stress for biological processes.
Conclusions
We have created a comprehensive dataset of methylation sites with a substantial effect on conferring resistance to anti-EGFR therapy in CRC patients. In addition to identifying critical DMCs, the pathways hold potential as a rich source of predictive biomarkers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
University of Antwerp.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract